DK1491201T3 - Fremgangsmåder til reduktion af toksicitet af 5-fluoruracil med acylerede pyrimidinnukleosider - Google Patents

Fremgangsmåder til reduktion af toksicitet af 5-fluoruracil med acylerede pyrimidinnukleosider

Info

Publication number
DK1491201T3
DK1491201T3 DK04023557T DK04023557T DK1491201T3 DK 1491201 T3 DK1491201 T3 DK 1491201T3 DK 04023557 T DK04023557 T DK 04023557T DK 04023557 T DK04023557 T DK 04023557T DK 1491201 T3 DK1491201 T3 DK 1491201T3
Authority
DK
Denmark
Prior art keywords
fluorouracil
methods
pyrimidine nucleosides
reducing toxicity
acylated pyrimidine
Prior art date
Application number
DK04023557T
Other languages
English (en)
Inventor
Reid W Vonborstel
Michael K Bamat
Original Assignee
Wellstat Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp
Application granted granted Critical
Publication of DK1491201T3 publication Critical patent/DK1491201T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DK04023557T 1995-06-07 1996-06-06 Fremgangsmåder til reduktion af toksicitet af 5-fluoruracil med acylerede pyrimidinnukleosider DK1491201T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/472,210 US5968914A (en) 1987-10-28 1995-06-07 Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
EP96918461A EP0831849A4 (en) 1995-06-07 1996-06-06 METHODS OF REDUCING THE TOXICITY OF CHEMOTHERAPEUTIC AGENTS AND ANTIVIRALS WITH ACYLATED PYRIMIDE NUCLEOSIDES

Publications (1)

Publication Number Publication Date
DK1491201T3 true DK1491201T3 (da) 2006-07-31

Family

ID=23874595

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04023557T DK1491201T3 (da) 1995-06-07 1996-06-06 Fremgangsmåder til reduktion af toksicitet af 5-fluoruracil med acylerede pyrimidinnukleosider

Country Status (13)

Country Link
US (2) US5968914A (da)
EP (2) EP0831849A4 (da)
JP (3) JPH10511689A (da)
KR (1) KR19990022804A (da)
CN (1) CN1192149A (da)
AT (1) ATE320813T1 (da)
AU (1) AU724805B2 (da)
CA (1) CA2223640A1 (da)
DE (1) DE69635941T2 (da)
DK (1) DK1491201T3 (da)
ES (1) ES2257721T3 (da)
PT (1) PT1491201E (da)
WO (1) WO1996040165A1 (da)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691320A (en) * 1987-10-28 1997-11-25 Pro-Neuron, Inc. Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis
US7776838B1 (en) * 1987-10-28 2010-08-17 Wellstat Therapeutics Corporation Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
CA2213385A1 (en) * 1997-08-20 1999-02-20 Eng-Hong Lee Method of protecting against coccidiosis infections in poultry
WO1999008686A1 (en) * 1997-08-21 1999-02-25 Basf Aktiengesellschaft Use of uridine to counter 5-fluorouracil toxicity
US6136339A (en) * 1998-08-21 2000-10-24 Gardiner; Paul T. Food supplements and methods comprising lipoic acid and creatine
US7807654B2 (en) 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US7915233B1 (en) 1998-08-31 2011-03-29 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
EP1808177B1 (en) 1999-02-23 2018-08-08 The Regents of The University of California Methods of treatment of mitochondrial disorders
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
WO2002011668A2 (en) * 2000-08-09 2002-02-14 Kolon Industries, Inc. 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
AU2002306551A1 (en) * 2001-03-01 2002-09-19 Eli Lilly And Company Tumor treatement with a combination of a substrate of mrp5 and modulators of mrp5
DE10110355A1 (de) * 2001-03-03 2002-09-12 Ulrich Walker Bekämpfung von Nebenwirkungen
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US20030082228A1 (en) * 2001-05-09 2003-05-01 Inex Pharmaceuticals Corporation Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents
SE521676C2 (sv) * 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
US20030147813A1 (en) * 2002-02-07 2003-08-07 John Lyons Method for treating chronic myelogenous leukemia
EP1352910A1 (en) * 2002-04-10 2003-10-15 Grünenthal GmbH New analogs of nitrobenzylthioinosine
US6982253B2 (en) * 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US20040162263A1 (en) * 2002-10-31 2004-08-19 Supergen, Inc., A Delaware Corporation Pharmaceutical formulations targeting specific regions of the gastrointesinal tract
WO2004104022A2 (en) * 2003-05-16 2004-12-02 The General Hospital Corporation Compositions comprising pathogen elicited epithelial chemoattractant (eicosanoid hepoxilin a3), inhibitors thereof and methods of use thereof
US20050037992A1 (en) * 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
US20050059682A1 (en) * 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
ATE540679T1 (de) * 2004-04-29 2012-01-15 Taiho Pharmaceutical Co Ltd Verfahren zur verringerung der gastrointestinalen toxizität durch verabreichung von tegafur
US20080214606A1 (en) * 2004-06-18 2008-09-04 The Government of the United States of America as represented by The Secretary of the Dept. of ..... Methods for the Identification and Use of Compounds Suitable for the Treatment of Drug Resistant Cancer Cells
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
US20080255168A1 (en) * 2004-12-03 2008-10-16 Adherex Technologies, Inc. Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
US20060128653A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
US20060128654A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US7250416B2 (en) * 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070105792A1 (en) * 2005-11-04 2007-05-10 Dimartino Jorge F Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases
US20070117776A1 (en) * 2005-11-04 2007-05-24 John Lyons Low Dose Therapy Of DNA Methylation Inhibitors
CN101384623B (zh) * 2005-12-22 2013-07-24 常山凯捷健生物药物研发（河北）有限公司 白蛋白与治疗剂的预成型偶联物的制备方法
US7906518B2 (en) 2006-06-27 2011-03-15 Cbt Development Limited Therapeutic compounds
BRPI0713902A2 (pt) 2006-06-27 2012-11-27 Biovitrum Ab compostos terapêuticos
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
US20100316655A1 (en) * 2008-02-11 2010-12-16 Hall Matthew D Compounds with mdr1-inverse activity
CN102014919B (zh) * 2008-03-03 2015-02-25 托斯克公司 减少毒性的甲氨蝶呤佐剂及其使用方法
US9265785B2 (en) 2008-12-22 2016-02-23 The Board Of Trustees Of The University Of Illinois Compositions comprising decitabine and tetrahydrouridine and uses thereof
US9259469B2 (en) 2008-12-22 2016-02-16 The Board Of Trustees Of The University Of Illinois Compositions comprising decitabine and tetrahydrouridine and uses thereof
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
AU2010234637B2 (en) * 2009-04-06 2016-05-12 Taiho Pharmaceutical Co., Ltd. (2 ' -deoxy-ribofuranosyl) -1,3,4, 7-tetrahydro- (1,3) iazepin-2-0ne derivatives for treating cancer
AR076263A1 (es) * 2009-04-06 2011-06-01 Eisai Inc Composiciones y metodos para tratar cancer. uso.
AU2010234562B2 (en) * 2009-04-06 2016-05-12 Taiho Pharmaceutical Co., Ltd. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
US8617540B2 (en) * 2009-04-15 2013-12-31 Fox Chase Cancer Center Combinational chemotherapy treatment
EP2455787A1 (en) 2009-07-15 2012-05-23 Asahi Glass Company, Limited Process for production of laminate, and laminate
EP2348131A1 (en) 2010-01-22 2011-07-27 Institut Curie Low levels of cytidine deaminase as a marker for genetic predisposition to develop cancer
CN102775458B (zh) * 2011-05-09 2015-11-25 中国人民解放军军事医学科学院毒物药物研究所 β-D-(2’R)-2’-脱氧—2’-氟-2’-C-甲基胞苷衍生物的制备及用途
EP3431142B1 (en) 2011-08-30 2020-06-17 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
BR102013022567B1 (pt) * 2013-09-03 2021-09-21 Uniao Brasileira De Educacão E Assistência Uso de 6-hidroxi-2-piridonas e seus derivados na preparação de uma composição farmacêutica que atue pela inibição da enzima uridina fosforilase humana
CN104496972A (zh) * 2014-12-04 2015-04-08 浙江大学 一种新型替加氟药物共晶及其制备方法
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
SG11201707513QA (en) * 2015-05-29 2017-10-30 Univ Leland Stanford Junior Nucleoside agents for the reduction of the deleterious activity of extended nucleotide repeat containing genes
AU2016287585B2 (en) 2015-07-02 2020-12-17 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
CA3027118C (en) * 2016-06-28 2023-08-15 Cellix Bio Private Limited Compositions and methods for the treatment of cancer
RU2020108580A (ru) 2017-08-03 2021-09-03 Оцука Фармасьютикал Ко., Лтд. Лекарственное соединение и способы его очистки
AU2019215105B2 (en) 2018-02-01 2024-12-19 Pharma Cinq, Llc Compositions and devices for systemic delivery of uridine
WO2020036982A1 (en) 2018-08-14 2020-02-20 Tosk, Inc. Methods and compositions for treating mucositis
WO2020036975A1 (en) 2018-08-14 2020-02-20 Tosk, Inc. Methods and compositions for reducing fluorouracil induced toxicity
WO2020036974A1 (en) * 2018-08-14 2020-02-20 Tosk, Inc. Methods and compositions for reducing radiation induced toxicity
WO2020226889A1 (en) * 2019-05-07 2020-11-12 Wellstat Therapeutics Corporation Formulations of uridine triacetate in triacetin
US11446303B2 (en) 2019-06-21 2022-09-20 Tosk, Inc. Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
KR20230012572A (ko) * 2020-05-19 2023-01-26 셀릭스 바이오 프라이빗 리미티드 암을 치료하기 위한 약학 제형 및 이의 제조
EP4178581A4 (en) 2020-07-07 2024-06-05 Tosk, Inc. URIDINE PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF LUNG DISEASES
PT4210709T (pt) 2020-09-14 2026-02-04 Pharma Cinq Llc 2¿,3¿‐diacetiluridina substituída com acetoacetilo na posição 5¿
WO2022226312A1 (en) * 2021-04-22 2022-10-27 Clear Creek Bio, Inc. Combination nucleotide pool depletion for treatment of viral infections and cancers
CN113332305B (zh) * 2021-06-03 2022-08-16 中国医学科学院医药生物技术研究所 胞苷类化合物的脂质组合物
CN113336816B (zh) * 2021-06-03 2022-05-17 中国医学科学院医药生物技术研究所 胞苷类化合物及其抗肿瘤用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1297398A (da) * 1969-08-06 1972-11-22
US4017606A (en) * 1973-10-04 1977-04-12 The Upjohn Company Organic compounds and process
GB1473148A (da) * 1974-09-16 1977-05-11
DE3100478A1 (de) * 1981-01-09 1982-08-12 Dr. Thilo & Co GmbH, 8021 Sauerlach 5'ester von pyrimidinnucleosiden mit antiviraler wirksamkeit, verfahren zur herstellung und daraus hergestellte arzneimittel
DE3481191D1 (de) * 1983-07-20 1990-03-08 Teijin Ltd Antineoplastisches mittel.
JPS60174797A (ja) * 1984-02-21 1985-09-09 Funai Corp Ν−アロイルチミジン誘導体ならびに抗腫瘍活性物質の毒性低下剤
US5736531A (en) * 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
EP0712629B1 (en) * 1987-10-28 2003-06-18 Wellstat Therapeutics Corporation Acyl deoxyribonucleoside derivatives and uses thereof
CA1321994C (en) * 1987-10-28 1993-09-07 Reid Von Borstel Acylated uridine and cytidine and uses thereof
US4874602A (en) * 1988-02-22 1989-10-17 Paul Calabresi Reduction of the severity 3'-azido-3'-deoxythymidine-induced anemia using benzylacyclouridine
US5077280A (en) * 1988-04-12 1991-12-31 Brown University Research Foundation Treatment of viral infections
US4950466A (en) * 1988-06-22 1990-08-21 Paul Calabresi Reduction of the severity of 3'-azido-3'-deoxythymidine-induced anemia using a combination of benzylacyclouridine and dipyridamole
US5132291A (en) * 1989-01-24 1992-07-21 Gensia Pharmaceuticals, Inc. Antivirals and methods for increasing the antiviral activity of azt
DE69014562T2 (de) * 1989-01-24 1995-06-22 Gensia Pharma Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes.
US5141943A (en) * 1990-04-12 1992-08-25 Brown University Research Foundation 5-benzyl barbiturate derivatives
CA2111571C (en) * 1991-07-05 2005-08-23 Reid W. Von Borstel Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1994026761A1 (en) * 1993-05-14 1994-11-24 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides

Also Published As

Publication number Publication date
DE69635941D1 (de) 2006-05-11
ATE320813T1 (de) 2006-04-15
EP1491201B1 (en) 2006-03-22
JP2003201240A (ja) 2003-07-18
HK1072897A1 (en) 2005-09-16
DE69635941T2 (de) 2006-11-23
CA2223640A1 (en) 1996-12-19
JPH10511689A (ja) 1998-11-10
WO1996040165A1 (en) 1996-12-19
US6344447B2 (en) 2002-02-05
EP0831849A4 (en) 2003-03-26
EP1491201A1 (en) 2004-12-29
PT1491201E (pt) 2006-08-31
JP2009167213A (ja) 2009-07-30
CN1192149A (zh) 1998-09-02
EP0831849A1 (en) 1998-04-01
AU6111496A (en) 1996-12-30
US20010025032A1 (en) 2001-09-27
US5968914A (en) 1999-10-19
ES2257721T3 (es) 2006-08-01
KR19990022804A (ko) 1999-03-25
AU724805B2 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
DK1491201T3 (da) Fremgangsmåder til reduktion af toksicitet af 5-fluoruracil med acylerede pyrimidinnukleosider
ATE314077T1 (de) 5-fluoro-2',3'-ungesättigte pyrimidinnucleoside
WO2003062255A3 (en) Sugar modified nucleosides as viral replication inhibitors
DK0831852T3 (da) Nukleosider med anti-hepatitis B-virusaktivitet
AU7779994A (en) Stabilized oligonucleotides and their use
DE69703298D1 (de) Propargylethoxyamino nucleotide
AU6081294A (en) Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
UA29382C2 (uk) Карбоциклічні нуклеозиди 6-заміщеного пурину
ATE165004T1 (de) Ematiomerenreine beta-d-dioxolane nucleoside mit selektiver antihepatitis b-virus wirkung
AU4180996A (en) Suicide genes and combinations of pyrimidine nucleoside and nucleobase analogues with suicide genes for gene therapy
NO932289D0 (no) 2'-deoksy-2',2'-difluor(4-substituerte pyrimidin)nukleosider med antiviral- og anticanceraktivitet og mellomprodukter
CA2002648A1 (en) 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives
BG102647A (en) Acyclic nucleoside derivatives
AU9009191A (en) Synergistic combination for treating herpes infections
AU7881398A (en) Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
Grant Biochemical modulation of cytosine arabinoside
DE69406943D1 (de) Konformationell festgelegte nukleosidanaloge
GR3032614T3 (en) Monohydrate of (e)-2'-deoxy-2'-(fluoromethylene)cytidine
IT234661Y1 (it) Dispositivo di fissaggio per pannelli frontali regolabili di cassetti.
AU5312586A (en) Composition and method for treatment of tumors with UDPG
EP0453247A3 (en) Anti-viral compounds
DE69533856D1 (de) L-pyranosyl-nukleoside
DK586489D0 (da) Antivirale forbindelser
WO1996037214A3 (en) Compositions of interleukin and pyrimidine nucleosides
MX9801515A (es) Preparado de combinacion para la aplicacion en la demencia.